DE69434691D1 - Zubereitung für übertragung der aktive tumorspezifische immunisierung von einem immunisiertem allogenem knochenmarkspender - Google Patents

Zubereitung für übertragung der aktive tumorspezifische immunisierung von einem immunisiertem allogenem knochenmarkspender

Info

Publication number
DE69434691D1
DE69434691D1 DE69434691T DE69434691T DE69434691D1 DE 69434691 D1 DE69434691 D1 DE 69434691D1 DE 69434691 T DE69434691 T DE 69434691T DE 69434691 T DE69434691 T DE 69434691T DE 69434691 D1 DE69434691 D1 DE 69434691D1
Authority
DE
Germany
Prior art keywords
recipient
immunized
tumor
donor
hematopoietic cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434691T
Other languages
English (en)
Inventor
Larry W Kwak
Dan L Longo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69434691D1 publication Critical patent/DE69434691D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69434691T 1993-11-17 1994-11-16 Zubereitung für übertragung der aktive tumorspezifische immunisierung von einem immunisiertem allogenem knochenmarkspender Expired - Lifetime DE69434691D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/153,464 US5861158A (en) 1993-11-17 1993-11-17 Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor
PCT/US1994/013224 WO1995014080A1 (en) 1993-11-17 1994-11-16 Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor

Publications (1)

Publication Number Publication Date
DE69434691D1 true DE69434691D1 (de) 2006-05-18

Family

ID=22547332

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69434691T Expired - Lifetime DE69434691D1 (de) 1993-11-17 1994-11-16 Zubereitung für übertragung der aktive tumorspezifische immunisierung von einem immunisiertem allogenem knochenmarkspender

Country Status (8)

Country Link
US (1) US5861158A (de)
EP (1) EP0729507B1 (de)
JP (1) JPH09509649A (de)
AT (1) ATE322540T1 (de)
AU (1) AU701858B2 (de)
CA (1) CA2176738C (de)
DE (1) DE69434691D1 (de)
WO (1) WO1995014080A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE306937T1 (de) * 1996-02-16 2005-11-15 Biomira Usa Inc Impfstoff gegen tumore der b-lymphozyten
US6017537A (en) * 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
CN1231761C (zh) * 1998-12-23 2005-12-14 梅德塞克股份有限公司 一种检测装置及鉴定分子的方法
IL142802A (en) * 2000-04-27 2015-01-29 Enzo Therapeutics Inc Use of one or more HBV antigens for the preparation of oral pharmaceutical preparations for the treatment of a person with active HBV infection or hepatocellular carcinoma
US8372798B2 (en) * 2001-10-16 2013-02-12 Endo Pharmaceuticals Colorado, Inc. High-concentration protein formulations and method of manufacture
WO2014036488A1 (en) 2012-08-31 2014-03-06 Biovest International, Inc. Methods for producing high-fidelity autologous idiotype vaccines

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192537A (en) * 1984-03-30 1993-03-09 Cellcor Inc. Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
US5614610A (en) * 1984-12-21 1997-03-25 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
AU7873187A (en) * 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
US5126132A (en) * 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5470730A (en) * 1990-09-28 1995-11-28 Immunex Method for producing TH -independent cytotoxic T lymphocytes
US5460964A (en) * 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
US5556763A (en) * 1992-04-06 1996-09-17 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Evaluation and treatment of patients with progressive immunosuppression
US5296353A (en) * 1992-04-06 1994-03-22 The United States Of America As Represented By The Department Of Health And Human Services Evaluation and treatment of patients with progessive immunosuppression
US5635156A (en) * 1993-09-13 1997-06-03 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
US5514364A (en) * 1993-09-13 1996-05-07 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation

Also Published As

Publication number Publication date
ATE322540T1 (de) 2006-04-15
WO1995014080A1 (en) 1995-05-26
EP0729507B1 (de) 2006-04-05
US5861158A (en) 1999-01-19
CA2176738C (en) 2002-11-12
JPH09509649A (ja) 1997-09-30
AU1256495A (en) 1995-06-06
CA2176738A1 (en) 1995-05-26
AU701858B2 (en) 1999-02-04
EP0729507A1 (de) 1996-09-04

Similar Documents

Publication Publication Date Title
DE69521794D1 (de) Zellen mit mehreren geänderten epitopen auf einem oberflächeantigen zur verwendung in transplantation
AU567693B2 (en) Human monoclonal antibodies against bacterial toxins
DK0871414T3 (da) Fremgangsmåder til fremstilling af væv til implantering
DK0702563T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme
DE69333433D1 (de) Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
WO1998021334A3 (en) Antibody mg1 recognizing a small subset of human hematopoietic cells
HK1017270A1 (en) Method of ex vivo immunizing using heterologous intact bispecific and/or trispecific antibodies
AU1198288A (en) Monoclonal antibodies against melanoma-associated antigens, hybrid cell lines producing these antibodies, and use therefor
NO981374L (no) Dendrittcellestimulerende faktor
DE2967036D1 (en) Vaccine and method of making
DE69434691D1 (de) Zubereitung für übertragung der aktive tumorspezifische immunisierung von einem immunisiertem allogenem knochenmarkspender
DE69624937T2 (de) Verfahren zur verminderung der strahlentherapie oder der radiomimetischen chemotherapie bei der transplantation von hematopoietischen, pluripotenten zellen
DE69633494D1 (de) Verfahren zur verhinderung von transplantatabstossung
JPS6445398A (en) Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody
NO962827L (no) Monoklonale antistoffer mot antigener uttrykt av hematopoietider facilitatoriske celler
Moriwaki et al. Ploidy fluctuations of mouse plasma-cell neoplasm MSPC-1 during serial transplantation
Izzo et al. Preferential localization and rate of loss of labeled alloantibody from rat tumors and skin transplants carrying the corresponding alloantigen
Lewis et al. Foetal-associated material: its expression in long-term cultured human skin
WO1988000836A3 (fr) Immunosuppresseur et son procede de fabrication
ATE227585T1 (de) Behandlung mittels eisen-entzug kombiniert mit igg antikörper
Müller-Ruchholtz Mhc allograft immunogenicity Its Role in Bone Marrow Transplantation and Its Constant Downregulation
EP0089771A3 (de) ATCC HB 8116 und sein monoklonaler anti-h-y Antikörper, hyklonalan
Marin et al. Requirements for the production of high-titre C3 nephritic factor (NEF) antibody in vitro.
DE59814423D1 (de) Verfahren zur herstellung von humaneigenblutzytokinen
TW221711B (en) N-AFP monoclonal antibody and method of preparation thereof

Legal Events

Date Code Title Description
8332 No legal effect for de